ProCE Banner Activity


My Approach to COVID-19 Treatment in a Patient With Immunocompromise

Clinical Thought

Patients with immunocompromise or who are taking immunosuppressing medications are at high risk of severe outcomes from COVID-19. These patients are often taking medications that have clinically significant drug–drug interactions with some COVID-19 antivirals, and care must be taken to safely treat their COVID-19 infection.

Nurses: 0.25 Nursing contact hour

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: January 09, 2024

Expiration: January 08, 2025



Shivanjali Shankaran

Shivanjali Shankaran, MD

Associate Professor, 
Director, General Inpatient Infectious Diseases
Associate Director, Adult Antimicrobial Stewardship Program
Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Pfizer Inc.

Pfizer, Inc.

Target Audience

This educational program is intended for PCPs, including physicians and advanced practice providers (APPs), who care for nonhospitalized patients with COVID-19.

Program Learning Goal

The goal of this program is to improve learners’ knowledge and confidence navigating drug-drug interactions when prescribing COVID-19 antivirals in outpatient settings.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Employ COVID-19 antivirals in outpatient settings according to national treatment guidelines

  • Assess potential drug–drug interactions for COVID-19 antivirals to inform therapeutic decisions in nonhospitalized patients

  • Design optimized antiviral regimens for nonhospitalized patients with COVID-19, employing tools and resources to navigate drug–drug interactions


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shivanjali Shankaran, MD

Associate Professor, 
Director, General Inpatient Infectious Diseases
Associate Director, Adult Antimicrobial Stewardship Program
Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Shivanjali Shankaran, MD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from January 09, 2024, through January 08, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.